Citadel Advisors’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Citadel Advisors’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,787,311	Closed	-$3.66M	–	15884
2022 Q4	$3.66M	Sell	1,787,311 -21,675	-1%	-$66K	﹤0.01%	4407
2022 Q3	$6.26M	Buy	1,808,986 +16,678	+0.9%	+$75.9K	﹤0.01%	3514
2022 Q2	$7.55M	Buy	1,792,308 +18,617	+1%	+$44K	﹤0.01%	3070
2022 Q1	$5.39M	Buy	1,773,691 +130	+0%	+$498	﹤0.01%	4026
2021 Q4	$8.25M	Sell	1,773,561 -4,098	-0.2%	-$28.2K	﹤0.01%	3385
2021 Q3	$13.7M	Buy	1,777,659 +3,828	+0.2%	+$29.2K	﹤0.01%	2568
2021 Q2	$14.9M	Sell	1,773,831 -4,565	-0.3%	-$40.3K	﹤0.01%	2479
2021 Q1	$20.2M	Buy	+1,778,396	New	+$27.9M	0.01%	1949

Other funds holding DBTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's DBTX Position: Q1 2023 in Review

Citadel Advisors sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q1 2023, closing a stake of 1,787,311 shares — an estimated $3.66M sold.

Citadel Advisors first reported a position in DBTX in Q1 2021 and held it in 8 quarters. The position peaked at $20.2M in Q1 2021. 38 funds tracked by Wall St. Rank hold DBTX as of Q1 2023.

Citadel Advisors reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 1,787,311 Decibel Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $3.66M.
Citadel Advisors first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Citadel Advisors's Decibel Therapeutics, Inc. Common Stock position peaked at $20.2M in Q1 2021.
38 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.